Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-NT Farallon Capital Europe For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Mar 31
-
Form SC 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
-
Ladenburg Thalmann Upgrades Forte Biosciences Inc. (FBRX) to Buy
-
Zambia External Bondholder Steering Committee Reaches Agreement with Zambia on Debt Restructuring
-
Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases
-
Geron Corp (GERN) Prices $150M Share and Warrant Offering at $3/sh
-
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Spyre Therapeutics (SYRE) announced $180M private placement
-
Spyre Therapeutics Announces $180 Million Private Placement
-
Form D/A Farallon Capital Institu
-
Form D/A Farallon Capital (AM)
-
Form D/A FARALLON CAPITAL OFFSHOR
-
Form D/A Farallon Capital Partner
-
Ventyx Biosciences (VTYX) Prices 11.17M Share Offering at $8.95/sh
-
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
-
FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio
-
Form SC 13G/A Forte Biosciences, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-NT Farallon Capital Europe For: Dec 31
-
Form SC 13G/A Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
Cliffwater Enhanced Lending Fund Adds Nicholas Lenicheck to Growing Platform
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form SC 13G/A AGIOS PHARMACEUTICALS, Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Aramark Filed by: Farallon Capital Partners, L.P.
-
Form SC 13D/A Cazoo Group Ltd Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Swiftmerge Acquisition Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Savara Inc Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Marblegate Acquisition Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Berenson Acquisition Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Longboard Pharmaceutical Filed by: Farallon Capital Partners, L.P.
-
AVROBIO Inc. (AVRO) and Tectonic Therapeutic Announce Merger
-
AVROBIO and Tectonic Therapeutic Announce Merger
-
Form SC 13G/A ENANTA PHARMACEUTICALS Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A Forest Road Acquisition Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A AVROBIO, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SC 13G/A SDCL EDGE Acquisition Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Clever Leaves Holdings Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G Elevation Oncology, Inc. Filed by: Farallon Capital Partners, L.P.

